Fennec announces TGH Cancer Institute study of PEDMARK for ototoxicity in AYA and adult patients

FENNEC PHARMACEUTICALS INC.

Tampa General Hospital Cancer Institute initiates real-world study of PEDMARK (sodium thiosulfate) to reduce ototoxicity risk in AYA and adult patients receiving cisplatin.
Study aims to evaluate clinical utility and audiology monitoring to inform future research on hearing loss prevention.
PEDMARK currently FDA-approved for pediatric patients 1 month+ with localized non-metastatic solid tumors; NCCN 2A recommendation for AYA.
Gene A. Wetzstein, PharmD, BCOP, of TGH Cancer Institute is principal investigator; Fennec's CMO Pierre Sayad comments on real-world evidence.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.